Peptide Capacity Looks Like It's Expanding Everywhere. The Facilities Tell a Different Story.

The peptide manufacturing industry has never attracted more attention. Nearly every month brings a new facility, an automation platform, a discovery technology, an AI-enabled design tool, or an expanded research service. At first glance, global peptide capacity looks like it is expanding everywhere at once.

A closer look at the facilities themselves tells a different story. Of more than twenty verified announcements across sixteen companies, only a small number add qualified, commercial-scale peptide API capacity capable of supplying Phase III and commercial programs. The rest are research, discovery, automation, or development-scale plays. And in 2026, the commercial tier didn't just concentrate — it consolidated.

What the data shows Findings from the CDMO Hub Peptide Facility Tracker (2024–2026): 20+ verified facility announcements across 16 companies.

• Three parent groups account for essentially all of the large-scale commercial peptide API expansion: CordenPharma, Bachem, and PolyPeptide.
• The "big four" is now a big three. Two independent leaders were absorbed in 2026 — AmbioPharm into CordenPharma, and PolyPeptide into Samsung Biologics.
• Concentration is high and tightening. Market-research estimates put the top five CDMOs at roughly half of global capacity, with a large share of manufacturers running above 80% utilization through 2025.
• Most tracked announcements are not commercial API expansion at all — they are discovery platforms, automation, research services, or development-scale manufacturing.
• Capacity cannot be added quickly. Solid-phase peptide synthesis (SPPS) does not scale by adding tanks, so most announced capacity is years from meaningful commercial output.

Looking Beyond the Headlines

The peptide industry spans a broad ecosystem — drug discovery platforms, AI-assisted design, research-grade synthesis, custom peptide services, clinical manufacturing, and commercial GMP API production. These often travel under the single banner of "peptide manufacturing," but they are entirely different business models.

For a company preparing to outsource, the question that matters is not who is investing in peptides. It is who is adding qualified commercial capacity capable of supplying late-stage and commercial products. That distinction only grows sharper as GLP-1 and next-generation metabolic therapies keep pulling demand forward.

Commercial Capacity Is Concentrated — and Consolidating

Almost every significant commercial-scale expansion in the tracker traces back to three parent groups. The 2026 wave of M&A has made that concentration more pronounced, not less.

These are not incremental lab upgrades. They are new manufacturing campuses, additional SPPS reactor trains, expanded GMP suites, and facilities designed to carry commercial production through the next decade.

Consolidation Is Now a Defining Force

The most important development since our last review is not a new building. It is who owns the buildings.

In May 2026, CordenPharma acquired AmbioPharm, a US-headquartered peptide CDMO, folding its North Augusta, South Carolina site and, notably, a Shanghai facility into CordenPharma's network. The reported facility-level expansion at North Augusta runs to roughly US$121.9 million; the acquisition itself was completed on undisclosed terms. The Shanghai footprint is worth watching: a Western CDMO adding Chinese capacity even as BIOSECURE-era policy pushes supply chains the other way.

Weeks later, Samsung Biologics agreed to acquire PolyPeptide Group for $1.81 billion, taking six GMP plants that already produce GLP-1 APIs. For the first time, a top-tier biologics manufacturer has bought its way directly into commercial peptide supply.

The takeaway for buyers is straightforward. The already-short list of qualified commercial partners is now backed by deeper capital and consolidated ownership. That can mean more investment and more resilient supply — and it can also mean less negotiating room for sponsors who wait too long to secure capacity.

The Second Tier Expands More Selectively

Several established peptide organizations continue to invest, but with a narrower focus. Companies such as BioDuro, BCN Peptides, and JPT Peptide Technologies are adding clinical manufacturing, specialized technologies, niche therapeutic capabilities, and development services rather than large commercial API lines.

These suppliers remain attractive partners for early clinical development. But their investments are not expected to materially change global commercial manufacturing capacity in the near term.

Technology Investment Is Not Manufacturing Expansion

This is the distinction the tracker makes most visible. Several well-known peptide names are investing heavily — just not in commercial API manufacturing. GenScript, IRBM, Pepscan, Creative Peptides, and PeptiCom are concentrating on automation, discovery, AI-driven design, screening, and research services.

These investments strengthen innovation and accelerate drug discovery. They should not be read as meaningful additions to global GMP peptide production. A company can be highly innovative in peptide science without operating a single commercial-scale manufacturing asset — and for an outsourcing team, that difference is the whole game.

A Note on Scope: Capacity Built Before the Window

By design, a tracker covering only 2024–2026 announcements will understate qualified capacity that came online immediately beforehand. Japan's PeptiStar is the clearest example.

PeptiStar operates a commercial-scale peptide and oligonucleotide API facility in Settsu City, Osaka, comprising approximately 10,500 m² of floor space across separate R&D and GMP manufacturing buildings with multiple production lines. Its capabilities, disclosed primarily in 2022–2023, include a world-class microwave SPPS platform, a 300 L filter reactor among the largest of its kind in the industry, and a 500 L lyophilizer. Together, these support commercial production at a scale of several hundred kilograms per year.

The facility is designed to manufacture both standard therapeutic peptide APIs and more challenging molecules, including special and cyclic peptides incorporating non-natural amino acids.

PeptiStar's expansion predates the tracker's 2024–2026 announcement window and is therefore not captured within its scope. However, given the scale of its manufacturing capacity, it remains an important part of the global peptide API manufacturing base, illustrating that Asia-Pacific already has meaningful, qualified peptide API capacity beyond the projects included in the tracker.

Why This Matters for Peptide Buyers

1. Commercial-scale supplier choice remains genuinely limited. Dozens of companies participate in peptide development. Very few own the infrastructure required for large commercial programs — and consolidation has thinned the independent field further.
2. Most new capacity is being built around GLP-1. Current investment is dominated by metabolic-peptide demand. Capacity for other therapeutic peptide classes may stay comparatively constrained.
3. Clinical options are broader than commercial options. Sponsors can usually find multiple suppliers for early development. The qualified list narrows sharply at late-stage and commercial scale.
4. Constraints will not clear overnight. SPPS capacity cannot be scaled simply by adding reactors — new sites require specialized construction, solvent and waste-handling infrastructure, industrial-scale HPLC purification and lyophilization, and step-by-step regulatory validation. Many announced facilities still need equipment installation, qualification, process validation, inspection, and operational ramp-up before they produce commercial material. Supply pressure is therefore likely to persist through the remainder of the decade.

CDMO Hub Insight

Despite a steady drumbeat of announcements, only a handful of manufacturers are materially increasing global commercial peptide API capacity — and in 2026 that group became more concentrated through acquisition, not less. Most announcements between 2024 and 2026 involve technology platforms, research capabilities, automation, or development-scale manufacturing.

For outsourcing teams, two questions now separate signal from noise: is this commercial API capacity or something else, and who ultimately owns it? Getting both right is becoming central to any serious long-term peptide sourcing strategy.

Looking for peptide manufacturing partners? CDMO Hub helps biotech and pharmaceutical companies identify verified peptide CDMOs based on manufacturing capabilities, regulatory experience, scale, and therapeutic modality. Explore verified suppliers and peptide manufacturing capabilities at CDMOHub.ai.

Inside Peptide Manufacturing is a CDMO Hub series on the industrial side of the peptide category — capacity, chemistry, cost of goods, and the decisions that sit behind them.

Sources

• Samsung Biologics–PolyPeptide Group acquisition (announced July 2026): company statements and industry reporting.
• CordenPharma peptide-platform expansion (2024) and AmbioPharm acquisition (May 2026): CordenPharma press releases. Investment (€900 million over three years), contract backlog (€3 billion), and 2028 peptide-sales target per CordenPharma.
• Bachem facility investment programme (2023–2026) and US expansion (2026–2030): Bachem company disclosures and industry reporting.
• Peptide manufacturing concentration and capacity-utilization figures: "Peptide CDMO Market," Business Research Insights (2026). These are market-research estimates and vary by source.
• PeptiStar facility and technology profile (capabilities publicized 2022–2023): PeptiStar Inc. company materials.
• SPPS scale-up constraints and GLP-1 demand context: industry reporting and market analyses.